ABEONA THERAPEUTICS INC. Accretion Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Accretion Expense of $1.01 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2021-03-24
- ABEONA THERAPEUTICS INC. accretion expense for the quarter ending 2020-12-31 was $263.00K, a 10.04% increase year-over-year.
- ABEONA THERAPEUTICS INC. accretion expense for the quarter ending 2020-09-30 was $256.00K, a 8.02% increase year-over-year.
- ABEONA THERAPEUTICS INC. accretion expense for the quarter ending 2020-06-30 was $251.00K, a 8.19% increase year-over-year.
- ABEONA THERAPEUTICS INC. accretion expense for the quarter ending 2020-03-31 was $245.00K, a 63.33% increase year-over-year.
- ABEONA THERAPEUTICS INC. accretion expense for fiscal 2020 was $1.01M, a 18.30% increase from fiscal 2019.
- ABEONA THERAPEUTICS INC. accretion expense for fiscal 2019 was $858.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $519.00K derived: sum of 2 quarters · filed 2021-03-24 | $770.00K derived: sum of 3 quarters · filed 2021-03-24 | $1.01M 10-K · filed 2021-03-24 |
| 2020-09-30 | $256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $507.00K derived: sum of 2 quarters · filed 2020-11-09 | $752.00K 10-Q · filed 2020-11-09 | $991.00K derived: sum of 4 quarters · filed 2021-03-24 |
| 2020-06-30 | $251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $496.00K 10-Q · filed 2020-08-10 | $735.00K derived: sum of 3 quarters · filed 2021-03-24 | $972.00K derived: sum of 4 quarters · filed 2021-03-24 |
| 2020-03-31 | $245.00K 10-Q · filed 2020-05-06 | $484.00K derived: sum of 2 quarters · filed 2021-03-24 | $721.00K derived: sum of 3 quarters · filed 2021-03-24 | $953.00K derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $476.00K derived: sum of 2 quarters · filed 2021-03-24 | $708.00K derived: sum of 3 quarters · filed 2021-03-24 | $858.00K 10-K · filed 2021-03-24 |
| 2019-09-30 | $237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $469.00K derived: sum of 2 quarters · filed 2020-11-09 | $619.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $382.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $150.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |